Last updated on November 2017

A Randomized, Double-Blind, Event Driven, Multicenter, Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure


Brief description of study

A Randomized, Double-Blind, Event Driven, Multicenter, Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure

Detailed Study Description

The purpose of this study is to investigate if rivaroxaban in combination with standard care (the other medications you are currently taking for your heart failure (HF) and coronary artery disease (CAD)) can reduce the risk of a heart attack, stroke or death in patients with Chronic Heart Failure and Coronary Artery Disease. The safety of rivaroxaban will also be studied.

Clinical Study Identifier: TX3851

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Candida Barlow

St. John Clinical Research Institute
Tulsa, OK USA
  Connect »